Company Of The Day: Walmart

by Trefis Team
+11.40%
Upside
143
Market
160
Trefis
WMT
Wal-Mart
Rate   |   votes   |   Share

What?

Retail behemoth Walmart (NYSE:WMT) plans to launch its own brand of insulin called ReliOn, which will be available at Walmart pharmacies this week and at Sam’s Club pharmacies by mid-July.

Why?

Prices for insulin have been surging, proving a financial burden on people with diabetes. Walmart claims that its insulin could be between 58% to 75% cheaper versus branded products.

So What?

Walmart is looking to play a bigger role in the affordable healthcare space, with plans to open over 4000 clinics by 2029. Selling its own branded insulin could be a good starting point, given that the drug is relatively expensive and widely used.

See Our Complete Analysis For Walmart

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!